Form 4: Rocket Pharmaceuticals Executive Kinnari Patel Reports Stock Transactions

Kinnari Patel, a Rocket Pharmaceuticals executive, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• Kinnari Patel, President, Head of R&D, and Chief Operating Officer of Rocket Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On May 14, 2024, Patel acquired 3,990 shares of common stock and 5,553 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• On May 16, 2024, Patel disposed of 4,046 shares of common stock at a price of $23.35 per share.
• Patel directly owns 400,972 shares of common stock and indirectly owns 5,675 shares through a spouse and 104,927 shares through Adaptive Technology LLC.
• The transactions included the vesting of RSUs granted on February 14, 2022, February 14, 2023 and August 12, 2022.
• The sale of shares was to cover tax withholding obligations related to the vesting of RSUs.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by a company executive, with no inherent positive or negative sentiment. It reflects standard compensation practices and regulatory compliance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the overall impact is likely minimal as it is related to tax obligations from RSU vesting.

Key Dates